Drug Oncology

Venclexta

Payments companies reported to CMS as associated with Venclexta. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$4.9Massociated payments (2023-2025)

10,975clinicians with associated payments

5companies reporting

By year

2023 $2.1M

2024 $1.5M

2025 $1.2M

Payments reported as associated with Venclexta, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Hematology & Oncology $2.4M

Medical Oncology $790K

Hematology (Internal Medicine) $700K

Family $183K

Nurse Practitioner $147K

Physician Assistant $135K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Venclexta

These are the largest totals companies reported as associated with Venclexta. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

Clinician	Location	Specialty	Associated payments (2023-2025)
Thomas Leblanc	Durham, NC	Medical Oncology	$191,786.25
Ashish Shah	Springfield, NJ	Hematology & Oncology	$160,446.23
Catherine Coombs	Orange, CA	Hematology & Oncology	$98,415.83
Nakhle Saba	Baton Rouge, LA	Hematology & Oncology	$94,360.04
Mehrdad Abedi	Sacramento, CA	Hematology & Oncology	$79,723.62
Javier Pinilla-Ibarz	Tampa, FL	Hematology (Internal Medicine)	$77,019.70
Vincent Herrin	Jackson, MS	Hematology (Internal Medicine)	$68,138.50
James Dugan	Winston Salem, NC	Hematology (Internal Medicine)	$64,798.57
Leonid Shunyakov	Bolivar, MO	Medical Oncology	$64,780.92
Gail Roboz	New York, NY	Hematology & Oncology	$61,968.57

Prescribed Venclexta?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

What this means, and what it doesn't

These payments are legal and common. Drug and device makers routinely pay for meals at educational events, consulting, speaking, travel, and research. Companies are required by federal law to report them; that's why this data exists.
A payment is not evidence of wrongdoing. Most clinicians who accept industry payments provide excellent care. Research payments in particular often reflect participation in clinical trials.
Context beats raw numbers. A few hundred dollars in sandwiches over several years is typical. What's worth understanding is scale, source, and purpose, which is what this page shows.
The data comes from companies, not doctors. Figures are "as reported to CMS" by the paying companies. Clinicians can dispute records through CMS's official process.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.